ClinicalTrials.gg
TerminatedNCT04408755Updated May 30, 2025Results posted

Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

A Phase 3 interventional study of AVP-786 and Placebo in Agitation in Patients With Dementia of the Alzheimer's Type, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Terminated at 95 sites in 11 countries. Open to participants aged 50 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-05-30.

Primary conditionPsychomotor Agitation(the registry's first term)UnverifiedIs this wrong?The registry often attaches Psychomotor Agitation to studies about something else, and this study's title and listed conditions do not name it. No better condition is named, so the registry's term is kept.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Why this study was terminated
The AVP-786 program was discontinued, the recruitment was stopped and all participants are no longer being examined or receiving intervention.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
184
Allocation
Randomized
Ages
50 Years to 90 Years
Sex
All
01

Study summary

This study was conducted to evaluate the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) compared to placebo for the treatment of agitation in participants with dementia of the Alzheimer's type.

Read the detailed description

Eligible participants for this study had a diagnosis of probable Alzheimer's disease (AD) and had clinically significant, moderate/severe agitation secondary to AD.

This was a multicenter, randomized, double-blind, placebo-controlled study, consisting of 12 weeks of treatment. Screening occurred within 4 weeks prior to randomization. Following screening procedures for assessment of inclusion and exclusion criteria, eligible participants were randomized into the study.

184 participants were enrolled into the study.

Study medication was administered orally twice daily from Day 1 through Day 85.

02

Conditions studied

  • Agitation in Patients With Dementia of the Alzheimer's Type

Browse trials for

Keywords

  • Agitation
  • Dementia of the Alzheimer's type
  • Alzheimer's disease
  • AVP-786
  • Deudextromethorphan hydrobromide
  • Quinidine sulfate
03

In context

Psychomotor Agitation Unverified

231 studies on the registry are indexed under Psychomotor Agitation; 28 are open to participants now.

This study's enrollment of 184 is above the median of 100 across 188 interventional studies indexed under Psychomotor Agitation.

Browse Psychomotor Agitation studies →

Lead sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.

Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.

Compared within Psychomotor Agitation, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
50 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with a diagnosis of probable Alzheimer's disease according to the 2011 Neuropsychiatric Inventory Agitation/Aggression (NPI-AA) working groups criteria
  • Participants with , moderate-to-severe agitation for at least 2 weeks prior to Screening that interferes with daily routine per the Investigator's judgment
  • Participants who require pharmacotherapy for the treatment of agitation per the Investigator's judgment after an evaluation of reversible factors and a course of nonpharmacological interventions
  • Diagnosis of agitation must meet the International Psychogeriatric Association (IPA) provisional definition of agitation.
  • Participants meeting an additional predetermined blinded eligibility criterion, which will remain blinded to the clinical study site Investigators and staff
  • Participants with a reliable caregiver who is able and willing to comply with all study procedures, including adherence to administering study drug and not administering any prohibited medications during the course of the study, and who spends a minimum of 2 hours per day for 4 days per week with the participant

Exclusion criteria

Exclusion Criteria:

  • Participants with dementia predominantly of the non-Alzheimer's type (e.g., vascular dementia, frontotemporal dementia, Parkinson's disease, substance-induced dementia)
  • Participants with symptoms of agitation that are not secondary to Alzheimer's dementia (e.g., secondary to pain, other psychiatric disorder, or delirium)
  • Participants with co-existent or unstable systemic diseases that could confound the interpretation of the safety results of the study (e.g., [except skin basal-cell carcinoma], poorly controlled diabetes, poorly controlled hypertension, unstable pulmonary, renal or hepatic disease, unstable ischemic cardiac disease, dilated cardiomyopathy, or unstable valvular heart disease)
  • Participants with myasthenia gravis
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
184 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants who were enrolled in 1-week double-blind placebo lead-in Period A, were then randomized to receive AVP-786 matching placebo capsules, twice a day, for 11 weeks in Period B.

    Drug: Placebo

  • Experimental
    AVP-786-18

    Participants who were enrolled in 1-week double-blind placebo lead-in Period A, were then randomized to receive AVP-786-18 (d6-DM 18 milligrams (mg)/Q 4.9 mg) capsules, twice a day, for 11 weeks in Period B.

    Drug: AVP-786

  • Experimental
    AVP-786-42.63

    Participants who were enrolled in 1-week double-blind placebo lead-in Period A, were then randomized to receive AVP-786-42.63 (d6-DM 42.63 mg/Q 4.9 mg) capsules, twice a day, for 11 weeks in Period B.

    Drug: AVP-786

Interventions

06

What researchers measure

Primary outcomes

  1. Change From the End of Period A (Week 1) to Week 10 in the Cohen-Mansfield Agitation Inventory (CMAI) Composite Score

    The CMAI is used to assess the frequency of manifestations of agitated behaviors in elderly persons. It consists of 29 agitated behaviors that are further categorized into distinct agitation syndromes, also known as CMAI factors of agitation. These distinct agitation syndromes include aggressive behavior, physically nonaggressive behavior, and verbally agitated behavior. Each of the 29 items is rated on a 7-point scale of frequency (1 = never, 2 = less than once a week but still occurring, 3 = once or twice a week, 4 = several times a week, 5 = once or twice a day, 6 = several times a day, 7 = several times an hour). The ratings are based on the 2 weeks preceding assessment of the CMAI. Higher scores indicate higher frequency of agitated behaviours while lower scores indicate lower frequency of agitated behaviours.

    Time frame: Week 1 to Week 10

  2. Number of Participants With Treatment Emergent Adverse Events (TEAE) and Serious TEAE

    An adverse event (AE) is any untoward medical occurrence or unintended change (eg, physical, psychological, or behavioral), including inter-current illness, that does not necessarily have a causal relationship with the study treatment. A serious adverse event (SAE) is any AE occurring at any dose that results in death, life-threatening experience, persistent or significant disability/incapacity, in-patient hospitalization or prolongation of hospitalization or congenital anomaly/birth defect. TEAEs are all AEs (including serious and non-serious) which started after start of double-blind study drug treatment; or if the event was continuous from baseline and was worsening, serious, study drug related, or resulted in death, discontinuation, interruption or reduction of study therapy.

    Time frame: From randomization (Week 2) up to 30 days after last dose of study drug (Up to Week 16)

Secondary outcomes

  1. Change From the End of Period A (Week 1) to Week 10 in the Clinical Global Impression of Severity of Illness (CGIS) Score, as Related to Agitation

    The CGIS is an observer-rated scale that measures illness severity. The CGIS-Agitation is a 7-point (1-7) scale (1 = normal, not at all ill; 7 = among the most extremely ill patients) and assesses severity of agitation in this study. Higher scores indicate severe agitation while the lower scores indicate little or no agitation.

    Time frame: Week 1 to Week 10

07

Results

Posted May 30, 2025
Limitations and caveats
The study was prematurely terminated due to discontinuation of development of the AVP-786 compound.

Participant flow

Participants took part in the study at clinical sites in the North America and Europe from 13 July 2020 to 27 June 2024.

Period A (Placebo lead-in)
Participant flow — Period A (Placebo lead-in)
MilestoneAll EnrolledPlaceboAVP-786-18AVP-786-42.63
Started184000
Completed173000
Not completed11000
Withdrew: Other11000
Period B (Randomization Period)
Participant flow — Period B (Randomization Period)
MilestoneAll EnrolledPlaceboAVP-786-18AVP-786-42.63
Started0566057
Safety population0566057
Completed0444848
Not completed012129
Withdrew: Adverse event0301
Withdrew: Death0010
Withdrew: Lost to follow-up0110
Withdrew: Physician decision0010
Withdrew: Protocol deviation0100
Withdrew: Study subject withdrawal by parent or guardian0222
Withdrew: Study terminated by sponsor0153
Withdrew: Withdrawal by subject0321
Withdrew: Reason not specified0102

Outcome measures

PrimaryChange From the End of Period A (Week 1) to Week 10 in the Cohen-Mansfield Agitation Inventory (CMAI) Composite Score

The CMAI is used to assess the frequency of manifestations of agitated behaviors in elderly persons. It consists of 29 agitated behaviors that are further categorized into distinct agitation syndromes, also known as CMAI factors of agitation. These distinct agitation syndromes include aggressive behavior, physically nonaggressive behavior, and verbally agitated behavior. Each of the 29 items is rated on a 7-point scale of frequency (1 = never, 2 = less than once a week but still occurring, 3 = once or twice a week, 4 = several times a week, 5 = once or twice a day, 6 = several times a day, 7 = several times an hour). The ratings are based on the 2 weeks preceding assessment of the CMAI. Higher scores indicate higher frequency of agitated behaviours while lower scores indicate lower frequency of agitated behaviours.

Time frame:
Week 1 to Week 10

No measurements were reported for this outcome.

PrimaryNumber of Participants With Treatment Emergent Adverse Events (TEAE) and Serious TEAE

An adverse event (AE) is any untoward medical occurrence or unintended change (eg, physical, psychological, or behavioral), including inter-current illness, that does not necessarily have a causal relationship with the study treatment. A serious adverse event (SAE) is any AE occurring at any dose that results in death, life-threatening experience, persistent or significant disability/incapacity, in-patient hospitalization or prolongation of hospitalization or congenital anomaly/birth defect. TEAEs are all AEs (including serious and non-serious) which started after start of double-blind study drug treatment; or if the event was continuous from baseline and was worsening, serious, study drug related, or resulted in death, discontinuation, interruption or reduction of study therapy.

Time frame:
From randomization (Week 2) up to 30 days after last dose of study drug (Up to Week 16)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAE) and Serious TEAE
ParticipantsPlaceboAVP-786-18AVP-786-42.63
TEAEs201517
Serious TEAEs132
SecondaryChange From the End of Period A (Week 1) to Week 10 in the Clinical Global Impression of Severity of Illness (CGIS) Score, as Related to Agitation

The CGIS is an observer-rated scale that measures illness severity. The CGIS-Agitation is a 7-point (1-7) scale (1 = normal, not at all ill; 7 = among the most extremely ill patients) and assesses severity of agitation in this study. Higher scores indicate severe agitation while the lower scores indicate little or no agitation.

Time frame:
Week 1 to Week 10

No measurements were reported for this outcome.

Adverse events

Collected over From randomization (Week 2) up to 30 days after last dose of study drug (Up to Week 16). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/56 (0%)1/56 (1.8%)20/56 (35.7%)
AVP-786-181/60 (1.7%)3/60 (5%)14/60 (23.3%)
AVP-786-42.630/57 (0%)2/57 (3.5%)17/57 (29.8%)
Most frequent serious events
Most frequent serious events
EventPlaceboAVP-786-18AVP-786-42.63
Cerebrovascular accidentNervous system disorders0/562/600/57
VomitingGastrointestinal disorders1/560/600/57
Failure to thriveMetabolism and nutrition disorders1/560/600/57
SyncopeNervous system disorders1/560/600/57
AgitationPsychiatric disorders0/560/601/57
Mental status changesPsychiatric disorders0/560/601/57
Renal impairmentRenal and urinary disorders0/560/601/57
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/560/601/57
Cardio-respiratory arrestCardiac disorders0/561/600/57
Small intestinal obstructionGastrointestinal disorders0/561/600/57
Most frequent other events
Showing 10 of 60
Most frequent other events
EventPlaceboAVP-786-18AVP-786-42.63
DizzinessNervous system disorders4/560/603/57
Urinary tract infectionInfections and infestations2/564/600/57
DiarrhoeaGastrointestinal disorders3/560/601/57
FallInjury, poisoning and procedural complications2/563/602/57
Atrial fibrillationCardiac disorders2/561/600/57
HypotensionVascular disorders2/560/600/57
Skin lacerationInjury, poisoning and procedural complications0/561/602/57
Atrial flutterCardiac disorders1/560/600/57
Atrioventricular blockCardiac disorders1/560/600/57
Abdominal discomfortGastrointestinal disorders1/561/600/57

Baseline characteristics

Randomized population included all participants who were randomized in the double-blind period B of the study.

Age, Continuous
Age, Continuous(years)PlaceboAVP-786-18AVP-786-42.63Total
Mean76.5 ± 7.5273.9 ± 7.8574.8 ± 6.4775.0 ± 7.35
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboAVP-786-18AVP-786-42.63Total
Female364233111
Male20182462
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboAVP-786-18AVP-786-42.63Total
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander1001
Black or African American55414
White505553158
More than one race0000
Unknown or Not Reported0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboAVP-786-18AVP-786-42.63Total
Ethnicity — Hispanic or Latino323936107
Ethnicity — Not Hispanic or Latino22192061
Ethnicity — Other2215
08

Study locations

95 sites
  • Clinical Research Site #840-081
    Fort Smith, Arkansas 72901, United States
  • Clinical Research Site #840-035
    La Jolla, California 92093, United States
  • Clinical Research Site #840-084
    Los Angeles, California 70072, United States
  • Clinical Research Site #840-050
    Oceanside, California 92056, United States
  • Clinical Research Site #840-064
    Pasadena, California 91105, United States
  • Clinical Research Site #840-098
    Santa Ana, California 92705, United States
  • Clinical Research Site #840-090
    Basalt, Colorado 81621, United States
  • Clinical Research Site #840-009
    Atlantis, Florida 33462, United States
  • Clinical Research Site #840-056
    Brandon, Florida 33511, United States
  • Clinical Research Site #840-020
    Coral Gables, Florida 33134, United States
  • Clinical Research Site #840-059
    Doral, Florida 33166, United States
  • Clinical Research Site #840-131
    Hialeah, Florida 33012, United States
  • Clinical Research Site #840-039
    Jacksonville, Florida 32256, United States
  • Clinical Research Site #840-012
    Kissimmee, Florida 34744, United States
  • Clinical Research Site #840-069
    Maitland, Florida 32751, United States
  • Clinical Research Site #840-083
    Maitland, Florida 32751, United States
  • Clinical Research Site #840-118
    Miami, Florida 33032, United States
  • Clinical Research Site #840-004
    Miami, Florida 33126, United States
  • Clinical Research Site #840-125
    Miami, Florida 33126, United States
  • Clinical Research Site #840-104
    Miami, Florida 33144, United States
  • Clinical Research Site #840-133
    Miami, Florida 33165, United States
  • Clinical Research Site #840-042
    Miami, Florida 33175, United States
  • Clinical Research Site #840-003
    Miami, Florida 33467, United States
  • Clinical Research Site #840-036
    Orlando, Florida 32819, United States
  • Clinical Research Site 840-111
    Pembroke Pines, Florida 33024, United States
  • Clinical Research Site #840-096
    Pensacola, Florida 32503, United States
  • Clinical Research Site
    Pompano Beach, Florida 33064, United States
  • Clinical Research Site #840-079
    Tampa, Florida 33614, United States
  • Clinical Research Site #840-112
    Tampa, Florida 33615, United States
  • Clinical Research Site #840-046
    Tampa, Florida 33634, United States
  • Clinical Research Site #840-107
    West Palm Beach, Florida 33407, United States
  • Clinical Research Site #840-049
    Glen Burnie, Maryland 21061, United States
  • Clinical Research Site #840-093
    Rochester Hills, Michigan 48307, United States
  • Clinical Research Site #840-015
    Hattiesburg, Mississippi 39401, United States
  • Clinical Research Site #840-029
    West Long Branch, New Jersey 07764, United States
  • Clinical Research Site #840-097
    Bronx, New York 10466, United States
  • Clinical Research Site #840-072
    New Windsor, New York 12553, United States
  • Clinical Research Site #840-095
    Monroe, North Carolina 28112, United States
  • Clinical Research Site #840-060
    Canton, Ohio 44718, United States
  • Clinical Research Site #840-028
    Columbus, Ohio 43210, United States
  • Clinical Research Site #840-061
    Edmond, Oklahoma 73012, United States
  • Clinical Research Site #840-099
    Tulsa, Oklahoma 74136, United States
  • Clinical Research Site #840-115
    McKinney, Texas 75069, United States
  • Clinical Research Site
    The Woodlands, Texas 77381, United States
  • Clinical Research Site #840-025
    Richmond, Virginia 23236, United States
  • Clinical Research Site #100-115
    Pernik, 2300, Bulgaria
  • Clinical Research Site #100-112
    Pleven, 5800, Bulgaria
  • Clinical Research Site #100-106
    Plovdiv, 4002, Bulgaria
  • Clinical Research Site #100-102
    Sofia, 1408, Bulgaria
  • Clinical Research Site #100-111
    Sofia, 1408, Bulgaria
  • Clinical Research Site #100-105
    Varna, 9020, Bulgaria
  • Clinical Research Site #100-108
    Varna, 9020, Bulgaria
  • Clinical Research Site #100-113
    Veliko Tarnovo, 5006, Bulgaria
  • Clinical Research Site # 208-001
    Aalborg, Region Nordjylland 9000, Denmark
  • Clinical Research Site #208-002
    Aalborg, 9000, Denmark
  • Clinical Research Site #1 Site #233-002
    Tallinn, 11315, Estonia
  • Clinical Research Site #2 Site #233-004
    Tallinn, 11315, Estonia
  • Clinical Research Site #233-001
    Tartu, 50406, Estonia
  • Clinical Research Site #276-017
    Böblingen, Baden-Württemberg 71034, Germany
  • Clinical Research Site #276-005
    Bad Homburg Vor Der Höhe, Hessen 61348, Germany
  • Clinical Research Site #276-012
    Gera, Thüringen 935, Germany
  • Clinical Research Site 276-014
    Berlin, 13187, Germany
  • Clinical Research Site# 300-005
    Athens, 15125, Greece
  • Clinical Research Site #300-006
    Ioannina, 45500, Greece
  • Clinical Research Site #300-003
    Thessaloníki, 54645, Greece
  • Clinical Research Site #616-018
    Zabrze, Katowice 41-807, Poland
  • Clinical Research Site #616-009
    Bydgoszcz, Kujawsko-Pomorskie 85-023, Poland
  • Clinical Research Site #616-006
    Lublin, Lubelskie 20-093, Poland
  • Clinical Research Site #616-015
    Sochaczew, Mazowieckie 96-500, Poland
  • Clinical Research Site #616-013
    Bydgoszcz, 85-163, Poland
  • Clinical Research Site #616-004
    Kielce, 25-411, Poland
  • Clinical Research Site #616-008
    Lublin, 20-064, Poland
  • Clinical Research Site #616-010
    Lublin, 20-080, Poland
  • Clinical Research Site #616-012
    Poznan, 60-369, Poland
  • Clinical Research Site #616-005
    Poznan, 61-853, Poland
  • Clinical Research Site #616-001
    Pruszcz Gdanski, 83-000, Poland
  • Clinical Research Site #616-007
    Warszawa, 01-737, Poland
  • Clinical Research Site #620-007
    Guimarães, Braga 4835-044, Portugal
  • Clinical Research Site #620-004
    Braga, 4710-243, Portugal
  • Clinical Research Site #620-005
    Coimbra, 3000-075, Portugal
  • Clinical Research Site #620-002
    Torres Vedras, 2560-280, Portugal
  • Clinical Research Site #630-001
    Bayamon, 00961, Puerto Rico
  • Clinical Research Site #630-003
    Rio Piedras, 00935, Puerto Rico
  • Clinical Research Site #630-002
    San Juan, 00918, Puerto Rico
  • Clinical Research Site #630-005
    San Juan, 926, Puerto Rico
  • Clinical Research Site #804-006
    Dnipro, 49005, Ukraine
  • Clinical Research Site #804-003
    Kharkiv, 61068, Ukraine
  • Clinical Research Site #804-004
    Kiev, 8631, Ukraine
  • Clinical Research Site #804-005
    Kyiv, 04080, Ukraine
  • Clinical Research Site #804-007
    Lviv, 79021, Ukraine
  • Clinical Research Site #826-003
    Blandford Forum, DT11 7DD, United Kingdom
  • Clinical Research Site #826-004
    Crowborough, TN61NY, United Kingdom
  • Clinical Research Site #826-001
    Fulwood, PR2 9HT, United Kingdom
  • Clinical Research Site# 826-006
    Manchester, M25 3BL, United Kingdom
  • Clinical Research Site #826-002
    Motherwell, ML1 4UF, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data will be available after marketing approval in global markets or beginning 1-3 years following article publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/

Data sharing details ↗ · clinical-trials.otsuka.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2020 to primary completion in Jun 2024, 47 months.

Results were first posted in May 2025, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2020
First posted
May 29, 2020
StartActual
Jul 13, 2020
Primary completionActual
Jun 27, 2024
CompletionActual
Jun 27, 2024
Results first posted
May 30, 2025
Last update
May 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04408755
Responsible party
Sponsor
First posted
May 29, 2020
Start date
Jul 13, 2020
Primary completion
Jun 27, 2024
Completion
Jun 27, 2024
Results posted
May 30, 2025
Last update
May 30, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Deudextromethorphan · Quinidine

Start the discussion